多替阿巴拉米片国内多少钱？

On January 20, 2018, ViiV, a joint venture company under GlaxoSmithKline, launched the first complete antiviral treatment regimen drug with dolutegravir (also known as DTG in English) as the core in China. This is also the first complete single-pill compound treatment regimen in the field of HIV treatment in China. 

Dolutegravir tablets are composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. In 2016, GSK announced the launch of the integrase DTG (Tevicai) in China. This therapeutic agent has the advantages of small drug dosage, low resistance to drug resistance, and low probability of drug side effects. This time, doptabalamid tablets are based on DTG, an integrase inhibitor, as the core drug, coupled with a treatment plan of two backbone drugs, abacavir and lamivudine, and made into a single tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work. 

Dolutegravir tablets are the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection. Regarding the price of Dolutegra abalami tablets, the original drug is relatively expensive in China, priced at 2,880$/box. In comparison, Inbec, a box of 30 tablets produced by the Indian company Emcure, sells for about RMB 1,000, making it the most cost-effective version in the world.